強気
$14.03
シナリオ価格
$11.250
-0.187 (-1.66%)終値時点
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
While Brainsway Ltd shows promising growth potential with a current price of $11.25 and a forward P/E ratio of 17.92, the RSI of 32.42 indicates it is currently oversold. The recent FDA approval for their Deep TMS technology and a strategic investment of $3 million in Radial Health are positive catalysts. However, the stock has seen a 15.48% decline over the past 20 days, suggesting caution. Given these factors, it may be wise to hold rather than buy at this moment.
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

BrainsWay Partners with IPMG to Enhance Mental Health Treatments

BrainsWay Expands Medical Policy Coverage for SWIFT TMS Protocol

BrainsWay Announces Pilot Study Results on Depression Treatment

BrainsWay Publishes New Data on Depression Treatment

BrainsWay Reports 35% Revenue Growth in Q2 2026
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).
While Brainsway Ltd shows promising growth potential with a current price of $11.25 and a forward P/E ratio of 17.92, the RSI of 32.42 indicates it is currently oversold. The recent FDA approval for their Deep TMS technology and a strategic investment of $3 million in Radial Health are positive catalysts. However, the stock has seen a 15.48% decline over the past 20 days, suggesting caution. Given these factors, it may be wise to hold rather than buy at this moment.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。